天康生物股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 作为天康生物股份有限公司（以下简称"公司）的独立董事，2024 年度本 人严格按照《公司法》、《上市公司治理准则》、《上市公司自律监管指引第 1 号—主板上市公司规范运作》、《上市公司独立董事管理办法》等法律、法规的 规定，认真履行职责，充分发挥独立董事的独立作用，维护公司的整体利益，保 护了全体股东的合法权益。现将 2024 年度履行独立董事职责情况汇报如下： 一、独立董事基本情况 （一）工作履历、专业背景及兼职情况 （二）参与董事会各专门委员会情况 2024 年度任职期间，作为公司第八届董事会审计委员会、提名委员会及薪 酬与考核委员会委员，本人积极参加委员会开展的相关工作及会议，履行相应职 责，利用自身专业知识并结合公司实际情况，对公司相关工作提出建议。 2024 年度，审计委员会共计召开 7 次会议，提名委员会共计召开 2 次会议， 薪酬与考核委员会共计召开 1 次会议，本人均出席，并表决同意，无提出异议、 反对和弃权的情形。 陈克峰，男，中国国籍，汉族，本科学历。曾任北京隆安律师事务所（乌鲁 木齐分所）律师助理，新疆四至律师 ...

天康生物股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 作为天康生物股份有限公司（以下简称"公司）的独立董事，2024 年度本 人严格按照《公司法》、《上市公司治理准则》、《上市公司自律监管指引第 1 号—主板上市公司规范运作》、《上市公司独立董事管理办法》等法律、法规的 规定，认真履行职责，充分发挥独立董事的独立作用，维护公司的整体利益，保 护了全体股东的合法权益。现将 2024 年度履行独立董事职责情况汇报如下： 一、独立董事基本情况 （一）工作履历、专业背景及兼职情况 李刚，男，中国国籍，汉族，教授、硕士生导师、管理学博士。曾任新疆经 济管理干部学院讲师。现任公司第八届董事会独立董事、新疆财经大学会计系教 授，统一股份独立董事，新疆农牧业投资（集团）有限责任公司外部董事。 （二）独立性自查及说明 根据《上市公司独立董事管理办法》要求，本人对自身独立性进行自查并签 署了《独立董事独立性自查报告》，本人未在公司担任除独立董事、董事会专门 委员会委员以外的其他职务，也未在公司主要股东公司担任任何职务，与公司及 主要股东、实际控制人之间不存在直接或者间接利害关系或其他可能妨碍其进行 独立客 ...

天康生物股份有限公司 2025 年 4 月 29 日 经核查，公司在任独立董事李刚、陈克峰、屈勇刚的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事、董事会专门委员会委员以外的 其他职务，也未在公司主要股东单位担任任何职务，与公司及主要股东、实际控 制人之间不存在直接或者间接利害关系或其他可能妨碍其进行独立客观判断的 关系，因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号--主板上市公 司规范运作》中对独立董事独立性的相关要求。 天康生物股份有限公司董事会 关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号--主板上市公司规范运作》等的规定， 天康生物股份有限公司（以下简称"公司"）董事会对在任独立董事李刚、陈克 峰、屈勇刚的独立性情况进行评估并出具如下专项意见： ...

Financial Performance - The company's operating revenue for 2024 was CNY 17,175,805,190.11, a decrease of 9.72% compared to CNY 19,025,806,286.59 in 2023[16] - The net profit attributable to shareholders for 2024 was CNY 605,052,882.38, representing a significant increase of 144.38% from a loss of CNY 1,363,316,030.34 in 2023[16] - The basic earnings per share for 2024 was CNY 0.44, compared to a loss of CNY 1.01 in 2023, marking a 143.56% improvement[16] - The total assets at the end of 2024 amounted to CNY 17,562,512,271.12, an increase of 4.84% from CNY 16,751,659,614.41 at the end of 2023[16] - The net cash flow from operating activities for 2024 was CNY 1,161,865,306.32, down 33.68% from CNY 1,751,811,265.78 in 2023[16] - The weighted average return on equity for 2024 was 9.01%, a significant recovery from -19.18% in 2023[16] - The net profit after deducting non-recurring gains and losses for 2024 was CNY 558,836,996.66, compared to a loss of CNY 1,378,079,973.60 in 2023, reflecting a 140.55% increase[16] Revenue Breakdown - The company achieved total operating revenue of CNY 1,717,580,520.11, a decrease of 9.72% compared to the previous year[40] - The feed business revenue was CNY 534,479,850, a decline of 17.67%, accounting for 31.12% of total revenue[40] - The pharmaceutical business revenue was CNY 99,852,020, an increase of 0.22%, representing 5.81% of total revenue[41] - The revenue from pig farming and food processing increased by 11.11% to CNY 615,655,280, making up 35.84% of total revenue[42] - The company sold 206,384 thousand doses of animal vaccines, a growth of 18.44% year-on-year[41] Investment and R&D - The company invested over CNY 200 million in a high-level biosafety laboratory, which was completed and put into use in 2020[39] - The company has over 400 R&D personnel and has obtained more than 20 national new veterinary drug certificates and over 200 patents[39] - The company’s total R&D investment amounted to CNY 206,652,390.30, a decrease of 22.79% from CNY 267,665,996.63 in the previous year[58] - The proportion of R&D investment to operating revenue decreased from 1.41% to 1.20%[58] - The number of R&D personnel decreased by 7.36% from 435 to 403[58] Cash Flow and Financial Management - The company reported a net cash flow from operating activities of CNY 1,161,865,306.32, a decrease of 33.68% compared to the previous year[60] - The company’s financing activities generated a net cash flow of -CNY 130,869,098.67, an improvement of 91.31% from the previous year[61] - The company’s investment activities saw a net cash outflow of CNY 750,018,757.17, a slight improvement of 3.22% compared to the previous year[61] - The company achieved a net increase in cash and cash equivalents of CNY 280,977,450.48, a significant increase of 153.18% compared to the previous year[61] Governance and Management - The company maintains strict independence from its controlling shareholder, ensuring separate operations in personnel, assets, and finances[105] - The board of directors consists of seven members, with three independent directors, meeting legal requirements for governance[106] - The supervisory board is composed of three members, including one employee representative, adhering to legal standards[108] - The company actively manages investor relations, organizing events such as the 2023 annual performance briefing to enhance communication with investors[109] - The company has established a complete and independent financial accounting system, ensuring financial decisions are made autonomously[114] Environmental Compliance - The company holds multiple pollution discharge permits with validity extending to 2026 and beyond, indicating compliance with environmental regulations[157] - The company reported a chemical oxygen demand (COD) of 13.9195 mg/L at the wastewater discharge point, which is below the standard limit of 150 mg/L for ammonia nitrogen[160] - The total nitrogen concentration at the wastewater treatment facility was recorded at 14.137 mg/L, indicating compliance with environmental standards[160] - The company has implemented measures to ensure that nitrogen oxides emissions are below the threshold of 1060 mg/m³, adhering to environmental regulations[160] - The company is continuously improving its environmental performance through the adoption of new technologies and compliance with updated standards[160] Shareholder Engagement - The company commits to distributing cash dividends of no less than 10% of the annual distributable profit for the next three years[175] - The company plans to conduct cash dividends annually, with the board able to propose mid-term cash distributions based on profitability and financial status[175] - The first temporary shareholders' meeting of 2024 had an investor participation rate of 30.45% on March 11, 2024[117] - The second temporary shareholders' meeting of 2024 had an investor participation rate of 30.04% on April 18, 2024[117] - The annual shareholders' meeting for 2023 had an investor participation rate of 31.51% on May 20, 2024[117]

Investment Rating - The report maintains a "Recommended" investment rating for the industry, suggesting a potential upside of over 15% relative to benchmark indices [4]. Core Insights - The swine industry shows stable breeding profits, with a focus on capacity reduction logic. The average price of external three yuan pigs was 15.0 CNY/kg, up 2.1% week-on-week, while the average weight of pigs sold was 128.6 kg, down 0.2% [19][20]. - The beef industry is at an inflection point, with strong price performance continuing. The average price of calves was 28.2 CNY/kg, up 2.1%, and the average price of fattened cattle was 25.8 CNY/kg, up 0.7% [23][30]. - The white chicken market is affected by ongoing avian influenza, with significant impacts on breeding stock and prices. The average price of white feather broiler chicks was 2.8 CNY/chick, up 9.5% [31][34]. - The animal health sector is seeing a recovery in demand as breeding supply stabilizes, with a notable increase in the issuance of vaccines [48][49]. Summary by Sections Swine Industry - The average price of external three yuan pigs was 15.0 CNY/kg, reflecting a week-on-week increase of 2.1%. The average weight of pigs sold was 128.6 kg, down 0.2%. The price of 15 kg external three yuan piglets was 668 CNY/head, with a slight decrease of 0.05% [19][21]. - Supply pressure remains stable, with normal sales rhythms from large producers and limited sales from smallholders. The demand side shows increased activity from secondary breeding, but overall consumption remains weak [20][21]. - The report recommends companies such as Muyuan Foods, Wens Foodstuff Group, and New Hope Liuhe for investment [20]. Beef Industry - The beef breeding industry is entering a capacity release phase, with the earliest signs of a price bottom forming. The report anticipates a potential recovery in the industry by late 2025 or early 2026 [23][30]. - The average wholesale price of beef was 61.4 CNY/kg, reflecting a slight increase of 0.2% [29][30]. - Recommended companies include Fucheng Co. and Guangming Meat Industry, focusing on integrated breeding and sales [23]. Poultry Industry - The average price of white feather broiler eggs was 1.6 CNY/egg, up 2.0%, while the average price of white feather broilers was 3.7 CNY/kg, up 2.2% [31][34]. - The report highlights the impact of avian influenza on breeding imports, particularly from the U.S. and New Zealand, which has been suspended for over three months [31][32]. - Recommended companies include Yisheng Livestock and He Feng Food [31]. Animal Health Sector - The demand for animal health products is expected to recover as breeding supply stabilizes. The issuance of vaccines has shown significant increases, particularly for swine diseases [48][49]. - The report recommends companies like Kexin Biological and Zhongmu Biotechnology, which are positioned to benefit from the recovery in the animal health market [49].

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2025-018 天康生物股份有限公司 关于部分募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、2020 年非公开发行股票募集资金基本情况 经中国证券监督管理委员会《关于核准天康生物股份有限公司非公开发行股票 的批复》(证监许可[2021]1771 号)核准，天康生物股份有限公司(以下简称"公司") 非公开发行不超过322,540,482股新股。本次非公开发行实际发行数量277,449,664 股，发行价格为人民币 7.45 元/股，募集资金总额为人民币 206,700.00 万元，扣 除承销保荐费共计 2,191.02 万元后，实际募集资金净额为人民币 204,508.98 万元。 上述募集资金到位情况已经希格玛会计师事务所(特殊普通合伙)验审，并出具了希 会验字(2021)0054 号《验资报告》。 二、募集资金存放和管理情况 (一)募集资金管理情况 为规范募集资金的管理和使用，保护投资者利益，公司根据《公司法》、《证 券法》、《深圳证券交易所股票上市规则》、 ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2025-017 天康生物股份有限公司 二、累计被冻结情况 截至公告披露日，上述股东及其一致行动人所持股份累计被冻结情况如下： | | | | | 持股份比例 | 总股本比例 | | --- | --- | --- | --- | --- | --- | | 股东名称 北京融元宝通资产管理 合伙企业（有限合伙） | 持股数量（股） 68,754,835 | 持股比例 5.04% | 累计被冻结数量（股） 68,754,835 | 合计占其所 100% | 合计占公司 5.04% | 三、其他情况及风险提示 1、截至公告披露日，北京融元宝通为公司持股 5%以上股东，不属于公司控股 股东或实际控制人及一致行动人，其所持股份被司法冻结事项不会导致公司控制 关于持股 5%以上股东所持公司股份被司法冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、本次股份被冻结的基本情况 天康生物股份有限公司（以下简称"公司"）于近日通过中国证券登记结算 有限责任公司深圳分公司系统查询，获悉公司持股 5%以 ...

Investment Rating - The investment rating for the agriculture, forestry, animal husbandry, and fishery industry is "Positive" (maintained) [1] Core Insights - The report highlights the potential for increased planting area due to the approval of the third batch of genetically modified crops, which includes 97 corn and 2 soybean varieties [5][15] - The report indicates that domestic companies focusing on high-yield genetically modified soybeans may benefit from reduced overseas supply due to trade tensions between China and the U.S. [6][17] - The report emphasizes the recovery potential in the pig farming sector, with rising prices supported by increased demand and reduced imports of meat [20][26] Summary by Sections Weekly Observation - The third batch of genetically modified crops has been approved, which is expected to increase the planting area significantly, with projections suggesting that the planting area for genetically modified corn may exceed 5 million acres by 2025 [5][15] - The approval of genetically modified crops aligns with national policies aimed at strengthening food security and promoting agricultural innovation [15][35] Weekly Viewpoint - The pig farming sector shows low valuation and recovery potential, with recommendations for companies such as Muyuan Foods and Wens Foodstuffs [26] - The pet food market is expected to grow significantly, driven by rising consumer spending and domestic brands gaining market share [29] Market Performance - The agriculture index outperformed the market by 6.38 percentage points, with significant gains in the planting sector [30][33] - Key stocks such as Western Animal Husbandry and Shennong Technology saw substantial increases in their share prices [34] Price Tracking - As of April 11, the average price of live pigs was 14.66 yuan/kg, reflecting a slight increase from the previous week [37] - The average price of beef also saw an increase, reaching 67.21 yuan/kg [43]

Group 1 - The poultry concept sector experienced a decline of 3.89%, ranking among the top losers in the market, with notable declines in companies such as Xiaoming Co., Xiangjia Co., and Huaying Agriculture [1] - The top gaining sectors included automotive chips with a rise of 6.04%, while the top losing sectors included genetically modified crops down by 5.96% and corn down by 5.84% [1] - The poultry sector saw a net outflow of 656 million yuan from major funds, with 21 stocks experiencing outflows, and 8 stocks seeing outflows exceeding 30 million yuan [1] Group 2 - The stock with the highest net outflow was Juxing Agriculture, with a net outflow of 116 million yuan, followed by Wens Foodstuffs and Tiankang Biological with outflows of 111 million yuan and 55.98 million yuan respectively [1] - Other companies in the poultry sector that faced significant net outflows included Tangrenshen, Lihua Co., and Yisheng Co. [1][2] - On the contrary, Yike Food and Chunxue Food were among the few stocks that saw net inflows, with 2.23 million yuan and 14,100 yuan respectively [1]

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2025-016 天康生物股份有限公司 关于签订募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 二、募集资金专户开立情况及三方监管协议签署情况 一、募集资金的基本情况 经中国证券监督管理委员会《关于核准天康生物股份有限公司非公开发行股票 的批复》(证监许可[2021]1771 号)核准，天康生物股份有限公司(以下简称"公司"） 非公开发行不超过322,540,482股新股。本次非公开发行实际发行数量277,449,664 股，发行价格为人民币 7.45 元/股，募集资金总额为人民币 206,700.00 万元，扣 除承销保荐费共计 2,191.02 万元后，实际募集资金净额为人民币 204,508.98 万元。 上述募集资金到位情况已经希格玛会计师事务所(特殊普通合伙)验审，并出具了希 会验字(2021)0054 号《验资报告》。 公司于 2025 年 3 月 6 日召开第八届董事会第二十三次（临时）会议和第八届 监事会第十五次（临时）会议，审议通过了《关于变更部分募 ...